InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
2024年3月29日 - 9:30AM
ビジネスワイヤ(英語)
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading
biopharmaceutical company announced that the first patient in China
has been dosed in the Phase 1b clinical study of the combination of
InnoCare’s novel SHP2 (Src Homology 2 domain containing protein
tyrosine phosphatase) allosteric inhibitor, ICP-189, with
ArriVent’s furmonertinib, a highly brain-penetrant, broadly active
mutation-selective EGFR (epidermal growth factor receptor)
inhibitor in patients with advanced or metastatic non-small cell
lung cancer (NSCLC).
NSCLC is the predominant subtype of lung cancer, accounting for
approximately 85% of all cases. In July 2023, InnoCare and ArriVent
BioPharma, Inc. (Nasdaq: AVBP) announced a clinical development
collaboration, accelerating the clinical trial of ICP-189 in
combination with furmonertinib in patients with advanced or
metastatic NSCLC in China.
Furmonertinib is being advanced by ArriVent in global studies in
patients with advanced or metastatic NSCLC with EGFR mutations,
including exon 20 insertion mutations. It is approved in China as a
first-line treatment for adults with locally advanced or metastatic
NSCLC with EGFR exon 19 deletion (19DEL) or exon 21 (L858R)
substitution mutations, where it is being further developed for
additional indications with Allist Pharmaceuticals (SSE: 688578)
who discovered furmonertinib. The U.S. Food and Drug Administration
(FDA) has granted Breakthrough Therapy designation for
furmonertinib for the treatment of patients with previously
untreated, locally advanced or metastatic NSCLC with EGFR exon 20
insertion mutations. Furmonertinib is also being evaluated for the
treatment of NSCLC patients with EGFR P-loop alpha-c helix
compressing (PACC) mutations.
ICP-189 is a potent and selective oral allosteric inhibitor of
SHP2, developed by InnoCare for the treatment of solid tumors as a
single agent and/or in combination with other antitumor agents.
Preliminary efficacy was observed in ICP-189 monotherapy. In the
dose escalation study, the dosage has been escalated up to 120 mg
with no DLT observed and a favorable PK and safety profile have
been demonstrated.
Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare,
said: “We are excited to see the latest progress of our clinical
collaboration with ArriVent. SHP2 inhibitors are ideal for the
treatment of solid tumors by combination with various targeted
drugs and immunotherapies and are expected to address the huge
unmet medical needs. We will accelerate the clinical study and
expect this innovative therapy to benefit more NSCLC patients
early.”
About InnoCare
InnoCare is a commercial stage biopharmaceutical company
committed to discovering, developing, and commercializing
first-in-class and/or best-in-class drugs for the treatment of
cancer and autoimmune diseases with unmet medical needs in China
and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai,
Guangzhou, Hong Kong, and United States. For more information,
please visit: http://www.innocarepharma.com.
Forward-looking Statements
This contains the disclosure of some forward-looking statements.
Except for statements of facts, all other statements can be
regarded as forward-looking statements, that is, about our or our
management's intentions, plans, beliefs, or expectations that will
or may occur in the future. Such statements are assumptions and
estimates made by our management based on its experience and
knowledge of historical trends, current conditions, expected future
development and other related factors. This forward-looking
statement does not guarantee future performance, and actual
results, development and business decisions may not match the
expectations of the forward-looking statement. Our forward-looking
statements are also subject to a large number of risks and
uncertainties, which may affect our short-term and long-term
performance.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328167713/en/
InnoCare Media
Chunhua Lu
86+10-66609879 chunhua.lu@innocarepharma.com
Investors
86+10-66609999 ir@Innocarepharma.com